AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in
Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the biotech to the leading pack of the migraine cure race, among Allergan, Amgen a
Summit Therapeutics has axed development of its Duchenne muscular dystrophy drug ezutromid after a spectacular failure in phase 2, causing the UK biotech's shares to plunge.